Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Ther Clin Risk Manag · 2016 · PMC4907732 · PMID 27354809

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Upon further examination, investigators classified a trend toward more adverse events to be possibly or probably related to linezolid (32.2%) as compared to dalbavancin (25.4%), although this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.